Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bladder cancer-associated protein (BLCAP) is a highly conserved, small transmembrane protein involved in tumor suppression by inhibiting cell proliferation and inducing apoptosis. Its expression is downregulated in various cancers, especially bladder and cervical cancer, and overexpression leads to growth arrest at the G1/S checkpoint and apoptosis via mechanisms involving RB1 (retinoblastoma protein), independently of p53 and NF-κB signaling. BLCAP modulates gene expression related to cell cycle and apoptosis and may be regulated by RNA editing (A-to-I) in multiple tissues, with altered editing or expression associated with cancer progression. BLCAP is under investigation as a diagnostic biomarker and a potential therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bladder cancer-associated protein (BLCAP).